New York (ots/PRNewswire) - Huma's predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education Huma Therapeutics Limited ("Huma"), a leading global digital health company, and Bayer, a leading global life sciences company, have ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - Data contributes to growing body of ...
- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful percutaneous coronary ...
Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...
DGAP-News: BB BIOTECH AG / Key word(s): Half Year Results BB Biotech shares hold steady in the second quarter (news with additional features) 20.07.2018 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of July 20, 2018 Interim report of BB Biotech AG as of June 30, 2018 BB Biotech shares hold steady in the second quarter - Substantial portfolio adjustments, new investments ...